What every dermatologist should know about Polycystic Ovary Syndrome (PCOS)

Similar documents
Acne pearls for adult female patients

Disclosures" Controversies in women s health 2017: Recognition and treatment of common disorders of the skin" A preview" Acne"

12/13/2017. Important references for PCOS. Polycystic Ovarian Syndrome (PCOS) for the Family Physician. 35 year old obese woman

Disclosures" Controversies in women s health 2016: Recognition and treatment of common disorders of the skin" A preview" Acne"

Polycystic Ovary Syndrome HEATHER BURKS, MD OU PHYSICIANS REPRODUCTIVE MEDICINE SEPTEMBER 21, 2018

12/27/2013. Kristen Cain, MD FACOG Reproductive Medicine Institute Sanford Health, Fargo ND

CREATING A PCOS TREATMENT PLAN. Ricardo Azziz, M.D., M.P.H., M.B.A. Georgia Regents University

Case Questions. Polycystic Ovarian Syndrome: Treatment Goals and Options. Differential Diagnosis of Hyperandrogenic Anovulation

Dr Stella Milsom. Endocrinologist Fertility Associates Auckland. 12:30-12:40 When Puberty is PCO

Overview of Reproductive Endocrinology

PCOS Awareness Symposium Atlanta September 24 th, Preventing Diabetes & Cardiovascular Disease in PCOS

Polycystic Ovary Syndrome

Case. 24 year old female presented to your office complaining of excess hair growth on her face and abdomen. Questions?

Polycystic Ovary Syndrome (PCOS):

16 YEAR-OLD OBESE FEMALE WITH OLIGOMENORRHEA

Hirsutism: Diagnosis and Treatment. Roger A. Lobo M.D. Columbia University

Polycystic Ovarian Syndrome. Heidi Hallonquist, MD Concord Hospital Concord Obstetrics and Gynecology

Polycystic Ovary Syndrome

Polycystic Ovary Syndrome

Amenorrhoea: polycystic ovary syndrome

REI CASE(S) Laura L. Tatpati, MD Division of REI, Dept of OB/GYN KUSM - W

METABOLIC RISK MARKERS IN WOMEN WITH POLYCYSTIC OVARIAN MORPHOLOGY

PCOS. Kirtly Parker Jones MD

Abnormal Uterine Bleeding Case Studies

The Impact of Insulin Resistance on Long-Term Health in PCOS

2-Hypertrichosis:- Hypertrichosis is the

JMSCR Vol 05 Issue 04 Page April 2017

PCOS IN ADOLESCENTS: EARLY DETECTION AND INTERVENTION

Polycystic ovary syndrome

Polycystic Ovary Disease: A Common Endocrine Disorder in Women

13 th Annual Women s Health Day PCOS. Saturday 02/09/2017 Dr Mathias Epee-Bekima O&G Consultant KEMH

Addressing Practice Gaps in PCOS

Polycystic Ovarian Syndrome: Diagnosis, Preconceptional Management and Health Risks

X/06/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 91(1):2 6 Copyright 2006 by The Endocrine Society doi: /jc.


WHY NEW DIAGNOSTIC CRITERIA FOR DIFFERENT PCOS PHENOTYPES ARE URGENTLY NEEDED

Polycystic Ovarian Syndrome: Diagnosis, Preconceptional Management and Health Risks. Kate D. Schoyer, M.D. May 6, 2016

Clinical and endocrine characteristics of the main polycystic ovary syndrome phenotypes

New PCOS guidelines: What s relevant to general practice

Polycystic Ovary Syndrome: Cardiovascular Disease risk

Polycystic ovary syndrome. Phenotypic comparison of Caucasian and Asian women with polycystic ovary syndrome: a cross-sectional study

Prevalence of Polycystic Ovarian Syndrome among urban adolescent girls and young women in Mumbai

Rotterdam Criteria 9/30/2017. A Changing Paradigm in PCOS. Polycystic Ovary Syndrome - Is the Cardiometabolic Risk Increased After Menopause?

Polycystic ovary syndrome

Prevalence and hormonal profile of polycystic ovary syndrome in young Kashmiri women presenting with hirsutism: A hospital based study

POLYCYSTIC OVARIAN SYNDROME WHERE WE ARE AT IN 2018

Clinical Profile Polycystic Ovarian Syndrome Cases

ROLE OF HORMONAL ASSAY IN DIAGNOSING PCOD DR GAANA SREENIVAS (JSS,MYSURU)

Assisted Reproductive. Technologies: Present and. Future

PCOS guidelines: What s relevant to general practice

What is PCOS? PCOS THE CONQUER PCOS E-BOOK. You'll be amazed when you read this...

POLYCYSTIC OVARIAN SYNDROME Laura Tatpati, MD Reproductive Endocrinology and Infertility. Based on: ACOG No. 108 Oct 2009; reaffirmed 2015

Cam type Femoroacetabular Impingement associated with Marker for Hyperandrogenism in Women

The prevalence of polycystic ovary syndrome in Iranian women based on different diagnostic criteria

PCOS. Reproductive Gynaecology and Infertility. Dr.Renda Bouzayen MD.FRCSC GREI,OBGYN Dalhousie University

Hyperandrogenism. Dr Jack Biko. MB. BCh (Wits), MMED O & G (Pret), FCOG (SA), Dip Advanced Endoscopic Surgery(Kiel, Germany)

Jannet Huang, MD, FRCPC, FACE, ABIHM, CCD, NCMP.

Clinical Problems in the Diagnosis and Treatment of PCOS During Adolescence

Polycystic Ovarian Syndrome (PCOS) LOGO

Prof.Dr. Nabil Lymon Head of Internal Medicine Department

JMSCR Vol 05 Issue 05 Page May 2017

Management of polycystic ovarian syndrome

UPDATE: Women s Health Issues

Disclosure. Outline. Obesity: Endocrine Issues as the Cause and as the Effect 4/5/2016

PCOS The intersection of sex hormones & metabolism. Educational Objectives. Presenter Disclosure Information. Polycystic Ovary Syndrome

Polycystic ovary syndrome in adolescence: diagnostic and therapeutic strategies

Infertility for the Primary Care Provider

Difference Between PCOS and Endometriosis

Polycystic Ovary Syndrome

Blood Pressure Measurement (children> 3 yrs)

UNDERSTANDING PCOS AND ITS DIAGNOSIS

International Journal of Advanced Research in Biological Sciences ISSN : Research Article

Nitasha Garg 1 Harkiran Kaur Khaira. About the Author

About PCOS. About PCOS

POLYCYSTIC OVARY SYNDROME INA S. IRABON,MD, FPOGS,FPSRM,FPSGE OBSTETRICS AND GYNECOLOGY REPRODUCTIVE ENDOCRINOLOGY AND INFERTILITY

Title of Guideline (must include the word Guideline (not protocol, policy, procedure etc)

3. Metformin therapy for PCOS

Female androgen profiles by MS for PCOS patients. CS Ho APCCMS 2010, Hong Kong 14 January 2010

The Relation between Diverse Phenotypes of PCOS with Clinical Manifestations, Anthropometric Indices and Metabolic Characteristics

INSULIN RESISTANCE, POLYCYSTIC OVARIAN SYNDROME An Overview

Determining the insulin resistance rate in Polycystic Ovary Syndrome patients (PCOs)

CARDIOVASCULAR EVENTS IN POLYCYSTIC OVARY SYNDROME

Clinical evaluation of hirsutism in South India

Diabetes: Across the Lifespan Friday, October 17, Obesity, Insulin Resistance and Type 2 Diabetes Cardiovascular Risks in Children.

Polycystic Ovary Syndrome

Female Reproductive Endocrinology

Update on Polycystic Ovary Syndrome What Dermatology Nurses and Nurse Practitioners Need to Know

Hirsutism - Management

Prevalence of polycystic ovarian syndrome in the Buraimi region of Oman

A STUDY OF CLINICAL PARAMETERS IN THE DIAGNOSIS OF POLYCYSTIC OVARIAN SYNDROME Soumya Ranjan Panda 1, K. Durgavati 2, Santhosh Kumar Sahu 3

THYROID PROFILE IN POLYCYSTIC OVARIAN SYNDROME Sudhanshu Sekhara Nanda 1, Subhalaxmi Dash 2, Ashok Behera 3, Bharati Mishra 4

POLYCYSTıC OVARY SYNDROME (PCOS) New Perspectives. Michel Abou Abdallah, MD. Reproductive Endocrinology

The Pharmacology of PCOS

The Severity of Menstrual Dysfunction as a Predictor of Insulin Resistance in PCOS

From the editors desk

Abnormal Uterine Bleeding

Pattern of dermatologic manifestations in polycystic ovarian disease cases from a tertiary care hospital

Metformin and Pioglitazone in Polycystic Ovarian Syndrome: A Comparative Study

Polycystic Ovary Disease: A Common Endocrine Disorder in Women

Evaluation of vitamin D3 in patients of polycystic ovary syndrome and their correlation

Transcription:

What every dermatologist should know about Polycystic Ovary Syndrome (PCOS) Kanade Shinkai, MD PhD University of California, San Francisco Associate Professor of Dermatology I have no conflicts of interest to disclose. I will be discussing off-label use of medications during this lecture.

Learning objectives Describe skin signs in PCOS and their reliability as disease markers Order appropriate diagnostic evaluation for patients suspected of having PCOS Select effective treatments for cutaneous manifestations of hyperandrogenism

Part I of III: What is PCOS? What skin findings do we see in PCOS?

Polycystic Ovary Syndrome (PCOS) Stein-Leventhal Disease Rotterdam criteria (2003): 2 of 3 oligomenorrhea (< 8 per year) serum or clinical hyperandrogenism ultrasound (+) polycystic ovaries Prevalence: 5-10% Heterogeneous phenotype Stein & Leventhal (1935) Am J Obstet Gynecol, 29:181-191 Rotterdam ESHRE/ASRM-sponsored PCOS Consensus Workshop Group (2004) Human Reproduc. 19:41-47

Why is it important to recognize PCOS? 10% develop diabetes in 3 rd or 4 th decade Endocrine 40% have impaired glucose tolerance 40% are obese CV Controversial Nurses Health Study Hyperlipidemia, hypertension, fatty liver Reproductive Subfertility Complications of pregnancy Oncologic Endometrial CA Association with obesity, type 2 DM Other Sleep apnea (30x risk) Quality of life (obesity, hirsutism) Norman RJ et al (2007) Lancet 370:685-697 Ehrmann DA (2005) NEJM 352:1223-1236

Cutaneous signs of PCOS Cross-sectional study 401 women suspected of having PCOS (69% PCOS+) Comprehensive skin exam by dermatologist 92% of patients with PCOS had skin finding Schmidt T et al (2015) JAMA Derm, Dec 23:1-8 Schmidt T et al (2016) manuscript submitted

Acne affects 61% of patients with PCOS 40% in high-risk population Sites: Face Trunk No systemic associations No significant QOL impact Not reliable marker of PCOS Schmidt T et al (2015) JAMA Derm, Dec 23:1-8 Beshay A et al (2015) unpublished results

Hirsutism is specific sign in PCOS

How is hirsutism measured? 1 2 3 4 Modified Ferriman-Gallwey 9 body sites Visual scale: 0 to 4 Total score: 36 (hirsutism >7) Mild: mfg 8-15 Moderate: mfg 16-25 Severe: mfg 26-36 Ferriman D, Gallwey JD (1961) J Clin Endo, 21:1140-1447 Hatch R et al (1981) Am J Obstet Gyn, 140:815-830

Hirsutism is most reliable sign of hyperandrogenism Multiple studies: 70-80% of patients with hirsutism meet PCOS criteria Hirsutism always warrants diagnostic evaluation Caucasian, East Asian women w/ PCOS: mfg comparable Increasing rate of hirsutism in higher Fitzpatrick skin types Fauser B et al (2012) Fertil Steril, 97:28-38 Escobar-Morreale H et al (2012) Human Repro Update, 18:146-170 Wang E et al (2013) Fert Steril, 100:214-218 Afifi L et al (2017) IJWD, in press

Hirsutism affects 53% of patients with PCOS 31% in high-risk population Important systemic associations Sites: Face Trunk Shoulders Thighs Schmidt T et al (2015) JAMA Derm, Dec 23:1-8

Hirsutism: how does it affect patients? Clinicians and patients do not see the same thing Clinician rating: 8.6 (range 0 31) Patient self-rating: 13.3 (range 1 33) 4.3 Patient ratings best predict depression and QOL impact Beck Depression Index Skindex-16: patients report significant QOL impact Pasch L et al (2016) JAMA Derm, 152:783

Acanthosis nigricans is specific sign in PCOS

Cannavo SP et al (2006) JEADV 20:478-480

Serin D (2005) Ophthal Plast Recon Surg 21:403-404 Peri-ocular acanthosis nigricans

Peri-oral acanthosis nigricans Ozhan B et al (2015) J Ped 167:1453

AN affects 37% of PCOS patients 20% in high-risk population Sites: Neck Axillary Central chest Inframammary Inguinal Knuckles Knees, elbows, face Schmidt T et al (2015) JAMA Derm, Dec 23:1-8 Metabolic associations

Part II of III: When should I worry about a hormonal disorder? How/ when to evaluate?

When should I worry about a hormonal disorder? Hirsutism, acanthosis nigricans Oligomenorrhea (<8 per year) or amenorrhea Virilization: Deepening voice Clitoromegaly Increased muscle mass Decreased breast size Virilization = sign of androgen-secreting tumor Azziz R et al (2004) J Clin Endo Metab, 89:453-462 Escobar-Morreale H et al (2012) Hum Reprod Update, 18:146-170 JC Harper (2008) J Drugs Derm 7: 527-530 Lolis MS et al (2009) Med Clin N Am 93:1161-1181

Hyperandrogenism workup: results PCOS Idiopathic HA Idiopathic Hirsutism NCCAH Tumors Misc 71% 15% 10% 3% 0.3% 0.7% PCOS is #1 cause of androgen excess Tumors, hormonal disorders are very rare Escobar-Morreale H et al (2012) Human Repro Update, 18:146-170

Diagnostic workup for PCOS Step 1: Endocrine When? Step 2: Metabolic Testosterone (free, total) 17-hydroxyprogesterone trans-vaginal ultrasound DHEA-S TSH prolactin androstenedione LH: FSH (>3 in 95% PCOS) BMI Blood pressure Fasting lipid panel Fasting insulin, glucose 2 hour glucose challenge HgbA1c ALT Schmidt TH, Shinkai K (2015) JAAD 73:672-690 Dizon M, Schmidt TH, Shinkai K (2016) Cutis, 98:11-13

Part III of III: What are the best treatments for women with skin signs of hyperandrogenism?

Focus on hirsutism: best practices Most: not FDA approved for hirsutism Prolonged (>6 months) medical therapy is needed (level B) Use effective contraception with anti-androgens (level B) Drosperinone dosage in OCP is not anti-androgenic (level B) Escobar-Morreale H et al (2012) Human Repro Update, 18:146-170

Off-label systemic treatments for hirsutism OCP Spironolactone Finasteride Flutamide 2B 1B 2C 2B mild hirsutism severe hirsutism category X side effects hepatotoxicity?additional benefit? Van Zuuren E, Fedorowicz Z (2015) JAMA, 314:1863-1864 Schmidt TH, Shinkai K (2015) JAAD 73:672-690 Fauser B et al (2012) Fertil Steril, 97:28-38 Escobar-Morreale H et al (2012) Human Repro Update, 18:146-170

Additional treatments for hirsutism Laser 1B IPL Eflornithine Metformin 0B,1C Statins Pio/troglitazone 50% reduction Limited evidence Van Zuuren E, Fedorowicz Z (2015) JAMA, 314:1863-1864 Schmidt TH, Shinkai K (2015) JAAD 73:672-690 Haedersdal M, Gotzsche PC (2006) Cochrane Database Syst Rev, CD004684 Escobar-Morreale H et al (2012) Human Repro Update, 18:146-170

Conclusions PCOS is most common cause of hyperandrogenism Best skin signs for PCOS: hirsutism, acanthosis nigricans Diagnostic evaluation before treatment Management of HA: delayed response, long-term treatment Important role of dermatologists in diagnosis, management, and advancement of our understanding of PCOS

Q&A